

Edoxaban outperforms edoxaban plus antiplatelet agent in patients with a-fib and stable coronary artery disease: Study

September 2 2024



Credit: Pixabay/CC0 Public Domain

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable coronary artery disease (CAD), according to late-breaking research presented in a Hot Line session Sept. 1 at [ESC Congress 2024](#).

The EPIC-CAD trial has been simultaneously [published](#) in the *New*

England Journal of Medicine.

"There was a lack of evidence regarding the best maintenance antithrombotic strategy in patients with high-risk AF and stable CAD, particularly as long-term dual therapy with an oral anticoagulant and an antiplatelet drug may increase the risk of bleeding.

"In the EPIC-CAD trial, we were able to show that edoxaban monotherapy resulted in fewer net adverse clinical events compared with dual antithrombotic therapy in the 12 months after randomization, with less clinically important bleeding and no increase in major ischemic events," said study presenter, Dr. Gi-Byoung Nam of the Asan Medical Center, Seoul, Republic of Korea.

The EPIC-CAD trial was an investigator-initiated, open-label, adjudicator-masked, randomized trial. Eligible patients had high-risk AF (CHA₂DS₂-VASc score ≥ 2) and stable CAD (if prior revascularization: after ≥ 12 months for [acute coronary syndrome](#) and after ≥ 6 months for chronic angina).

Patients were randomly assigned in a 1:1 ratio to either monotherapy of standard-dose edoxaban (60 mg once daily or 30 mg once daily with dose-reduction criteria) or dual antithrombotic therapy of standard-dose edoxaban plus a single antiplatelet agent (either aspirin or clopidogrel).

The primary endpoint was the net composite outcome of death from any cause, stroke, systemic embolism, [myocardial infarction](#), unplanned revascularization, and major or clinically relevant non-major bleeding at one year after randomization.

Key secondary endpoints included the individual components of the primary endpoint, a composite of major ischemic events (death, myocardial infarction, ischemic stroke and systemic embolism), and a

composite of major and clinically relevant non-major bleeding.

In total, 1,040 patients were randomized from 18 major cardiac centers in South Korea. The mean age was 72 years and 23% were women. The mean CHA₂DS₂-VASc score was 4.3. The mean HAS-BLED score was 2.1, indicating a moderate risk of bleeding.

Two thirds had undergone previous revascularization (66%) and the median time from last revascularization was 53 months. Patients in the dual antithrombotic therapy group more often received aspirin (62%) than clopidogrel (38%).

In the 12 months after randomization, edoxaban monotherapy significantly reduced the risk of the primary endpoint by 56% compared with dual antithrombotic therapy (6.8% vs. 16.2%; hazard ratio [HR] 0.44; 95% confidence interval [CI] 0.30–0.65; p

Citation: Edoxaban outperforms edoxaban plus antiplatelet agent in patients with a-fib and stable coronary artery disease: Study (2024, September 2) retrieved 4 September 2024 from <https://medicalxpress.com/news/2024-09-edoxaban-outperforms-antiplatelet-agent-patients.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.